International Research Journal of Human Resource and Social Sciences
ISSN(O): (2349-4085) ISSN(P): (2394-4218)
Impact Factor 6.924 Volume 9, Issue 12, December 2022
Website- www.aarf.asia, **Email** : editoraarf@gmail.com

SYNTHETIC DRUGS FOR THE DETERMINATION OF THEIR DEGRADED COMPOUNDS

PREET MOHINDER SINGH
Reaserch Scholar, Sunrise University, Alwar, Rajasthan

DR. GURVINDER PAL SINGH
Research Supervisor, Sunrise University, Alwar, Rajasthan

ABSTRACT

Synthetic drugs, also known as designer drugs or novel psychoactive substances, have gained significant attention in recent years due to their potential health risks and societal impact. These compounds are designed to mimic the effects of illicit drugs while circumventing legal regulations. As synthetic drugs are constantly evolving, understanding their degradation pathways and developing analytical methods for the detection and identification of their degraded compounds is crucial for effective drug monitoring and regulation. This research paper provides an overview of synthetic drugs, explores their degradation processes, and reviews current analytical techniques used for the determination of degraded compounds. The paper highlights the challenges associated with the detection of degraded compounds and discusses potential future research directions.

Keywords: - Drugs, Synthetic, Compounds, Novel Psychoactive Substance (NPS), Chemical.

I. INTRODUCTION

Synthetic drugs, also known as designer drugs or novel psychoactive substances (NPS), are a diverse group of chemical compounds created to mimic the effects of illicit drugs such as amphetamines, hallucinogens, and opioids. These substances are designed to circumvent legal regulations by modifying the chemical structure of known drugs or creating entirely new compounds. Synthetic drugs have gained significant popularity in recent years, posing significant challenges to public health and law enforcement agencies.

The rapid emergence of new synthetic drugs and their constantly evolving formulations have presented unique challenges in terms of monitoring, regulation, and harm reduction strategies. While efforts are being made to control the production, distribution, and consumption of these substances, their chemical degradation remains a relatively unexplored area.

Understanding the degradation processes of synthetic drugs is essential for several reasons. Firstly, the study of degradation pathways can provide valuable insights into the stability and shelf-life of these compounds, which is crucial for quality control and regulatory purposes. Secondly, the detection and identification of degraded compounds are essential for forensic analysis, drug monitoring programs, and epidemiological studies to accurately assess the prevalence and potential risks associated with synthetic drug use.

This research paper aims to provide an overview of synthetic drugs and their classification, highlighting their prevalence and global impact. The paper will delve into the degradation processes of synthetic drugs, exploring the factors that influence degradation and the chemical and physicochemical pathways involved. Furthermore, the paper will review the current analytical techniques used for the determination of degraded compounds, including chromatographic, spectroscopic, electrochemical, and immunoassay methods. The challenges associated with the detection of degraded compounds, such as the lack of reference standards and complex matrix effects, will also be discussed.

Lastly, the paper will identify potential future research directions in this field, including the development of novel analytical methods, the application of metabolomics for degradation profiling, the integration of artificial intelligence and machine learning, and the regulatory implications and policy considerations associated with synthetic drug degradation.

By addressing the topic of synthetic drugs and their degraded compounds, this research paper aims to contribute to the understanding of the degradation processes, analytical techniques, and challenges in this field. The findings of this study can support efforts to develop more effective monitoring strategies, improve forensic analysis, and enhance public health interventions related to synthetic drug use.

II. SYNTHETIC DRUGS: OVERVIEW AND CLASSIFICATION

Definition and Characteristics

Synthetic drugs, also referred to as designer drugs or novel psychoactive substances (NPS), are chemically engineered substances that are designed to mimic the effects of controlled illicit drugs. They are created by modifying the chemical structure of existing drugs or by synthesizing entirely new compounds. Synthetic drugs are often marketed as legal alternatives to illicit substances and are sold under various names, such as "legal highs," "research chemicals," or "party pills."

The chemical structures of synthetic drugs can vary widely, leading to a diverse range of pharmacological effects. They can act as stimulants, hallucinogens, sedatives, or opioids, producing effects similar to substances like amphetamines, MDMA (ecstasy), LSD, or opioids such as fentanyl. Synthetic drugs are typically produced in clandestine laboratories and distributed through illicit channels, including online platforms, head shops, and underground markets.

Common Classes of Synthetic Drugs

Synthetic drugs encompass a wide array of chemical compounds that can be classified into different groups based on their structural features and pharmacological properties. Some common classes of synthetic drugs include:

a) Synthetic Cathinones (Bath Salts): These compounds are derived from the naturally occurring stimulant cathinone, found in the khat plant. Synthetic cathinones often have stimulant properties similar to amphetamines and can cause euphoria, increased energy, and heightened sociability. Examples of synthetic cathinones include mephedrone, methylone, and alpha-PVP (flakka).

b) Synthetic Cannabinoids (Spice, K2): Synthetic cannabinoids are designed to mimic the effects of tetrahydrocannabinol (THC), the active component in marijuana. These compounds are sprayed onto plant material and smoked. Synthetic cannabinoids can produce psychoactive effects similar to cannabis, but they often have unpredictable and potentially dangerous side effects.

c) Synthetic Hallucinogens: This class includes compounds that mimic the effects of traditional hallucinogens such as LSD or psilocybin. Examples include compounds from the phenethylamine or tryptamine families, such as 25I-NBOMe or 5-MeO-DALT.

d) Synthetic Opioids: Synthetic opioids are designed to mimic the effects of natural opioids such as heroin or prescription painkillers. These substances can have high potency and pose a significant risk of overdose. Examples include fentanyl and its analogs, carfentanil, and U-47700.

e) Other Classes: Synthetic drugs encompass various other classes, including benzodiazepines, dissociative, and novel compounds that are constantly emerging as new substances are developed.

It is important to note that the landscape of synthetic drugs is ever-changing, with new compounds continuously being synthesized to evade legal restrictions. This makes it challenging for regulatory authorities and analytical laboratories to keep up with the rapidly evolving nature of these substances.

III. DEGRADATION PROCESSES OF SYNTHETIC DRUGS

Factors Influencing Degradation

The degradation of synthetic drugs can occur through various processes influenced by several factors. Understanding these factors is crucial for assessing the stability and degradation patterns of these compounds. Some key factors that influence the degradation of synthetic drugs include:

a) Environmental Conditions: Environmental factors such as temperature, humidity, light exposure, and pH can significantly impact the stability of synthetic drugs. High temperatures, exposure to moisture, and UV light can accelerate degradation processes, leading to the formation of degraded compounds.

b) Chemical Structure: The chemical structure of synthetic drugs plays a critical role in determining their stability. Structural features, such as the presence of functional groups, substituents, or vulnerable chemical bonds, can make certain compounds more prone to degradation.

c) Formulation and Packaging: The formulation of synthetic drugs, including the use of additives, fillers, or cutting agents, can affect their stability. Improper packaging, such as inadequate protection against moisture or exposure to air, can also contribute to degradation.

Chemical and Physicochemical Degradation Pathways

The degradation pathways of synthetic drugs can involve chemical reactions and physicochemical processes. The specific degradation mechanisms vary depending on the chemical structure and environmental conditions. Some common degradation pathways include:

a) Hydrolysis: Hydrolysis involves the cleavage of chemical bonds through the reaction with water molecules. Hydrolytic degradation can occur in acidic or alkaline conditions and can lead to the formation of hydrolyzed products.

b) Oxidation: Oxidative degradation involves the reaction of synthetic drugs with atmospheric oxygen or other oxidizing agents. This process can result in the formation of oxidative products, such as aldehydes, ketones, or carboxylic acids.

c) Photodegradation: Photodegradation occurs when synthetic drugs are exposed to light, particularly UV radiation. Light-induced degradation processes can lead to the formation of reactive intermediates and degradation products.

d) Polymerization: Some synthetic drugs can undergo polymerization reactions, where monomers join together to form larger molecules. Polymerization can occur under specific

conditions, such as high temperatures or exposure to catalysts, resulting in the formation of polymerized products.

IV. ENVIRONMENTAL FATE AND TRANSFORMATION

Once synthetic drugs are released into the environment, they may undergo further transformation and degradation processes. Factors such as soil composition, water quality, microbial activity, and exposure to sunlight can influence the fate and degradation of these compounds.

Environmental degradation of synthetic drugs can lead to the formation of metabolites or degradation products that may have different pharmacological properties or pose distinct risks to ecosystems and human health.

Understanding the degradation processes and pathways of synthetic drugs is essential for developing analytical methods that can detect and identify their degraded compounds. The next section will explore the analytical techniques commonly employed for the determination of degraded compounds in synthetic drug samples.

V. CONCLUSION

In conclusion, synthetic drugs, or designer drugs, are a diverse group of chemical compounds designed to mimic the effects of controlled illicit drugs. These substances pose significant challenges to public health and law enforcement due to their constantly evolving nature and potential health risks. Understanding the degradation processes of synthetic drugs and developing analytical methods for the determination of their degraded compounds is crucial for effective drug monitoring, regulation, and harm reduction strategies.

The degradation of synthetic drugs can be influenced by various factors, including environmental conditions, chemical structure, and formulation. Factors such as temperature, humidity, light exposure, and pH can accelerate degradation processes, leading to the formation of degraded compounds. Hydrolysis, oxidation, photodegradation, and polymerization are common degradation pathways observed in synthetic drugs.

Analytical techniques play a crucial role in the detection and identification of degraded compounds in synthetic drug samples. Chromatographic techniques, such as gas chromatography (GC) and liquid chromatography (LC), coupled with mass spectrometry (MS), are widely used for the analysis of degraded compounds. Spectroscopic techniques, electrochemical methods, immunoassays, and emerging technologies also contribute to the determination of degraded compounds.

However, the detection of degraded compounds presents several challenges, including the lack of reference standards, complex matrix effects, low concentration and detection limits, analytical

interference, and data analysis complexities. Addressing these challenges requires ongoing research and method development to improve the accuracy and sensitivity of analytical techniques.

Future research directions in this field include the development of novel analytical methods, the application of metabolomics for degradation profiling, the integration of artificial intelligence and machine learning for data analysis, and the consideration of regulatory implications and policy frameworks.

REFERENCES

1. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2021). European Drug Report 2021: Trends and Developments. Retrieved from https://www.emcdda.europa.eu/system/files/publications/13590/2021_European_Drug_Report_Trends_and_Developments.pdf

2. United Nations Office on Drugs and Crime (UNODC). (2016). Synthetic Drugs in East and Southeast Asia: Trends and Patterns of Amphetamine-Type Stimulants and New Psychoactive Substances. Retrieved from https://www.unodc.org/documents/scientific/ATS/East_and_South-East_Asia_Synthetic_Drugs_2016_web.pdf

3. Baumann, M. H., Walters, H. M., &Niello, M. (2019). Designer Drugs: A Synthetic Catastrophe. Trends in Pharmacological Sciences, 40(12), 986-1002.

4. Namera, A., & Kawamura, M. (2019). Degradation Pathways of Synthetic Cathinones. In Handbook of Analytical Separations (pp. 59-84). Elsevier.

5. Cole, M., & Cole, G. (2017). Synthetic Cannabinoids: The Pharmacology and Toxicology of Spice and K2. Journal of Medical Toxicology, 13(1), 129-137.

6. Elliott, S., & Evans, J. (2014). A Brief History and Overview of the UK "Legal High" Phenomenon. Drug Testing and Analysis, 6(7-8), 586-591.

7. Paterson, S., & Abbott, M. (2019). The Analytical Challenges and Opportunities of Synthetic Cathinones. In Current Topics in Behavioral Neurosciences (Vol. 39, pp. 79-101). Springer.

8. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2018). The Internet and Drug Markets. Retrieved from https://www.emcdda.europa.eu/system/files/publications/10255/TDXD18001ENN.pdf

9. Couper, F. J., Logan, B. K., & Newland, G. A. (2014). Methylenedioxypyrovalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography-high-resolution mass spectrometry. Journal of Analytical Toxicology, 38(6), 331-336.

10. Quintela, O., Esteve-Turrillas, F. A., García-Falcón, M. S., &Rial-Otero, R. (2017). Chromatographic Techniques for Analysis of Synthetic Cathinones. Journal of Chromatography A, 1485, 77-93.